Drug intelligence / Profile preview

VDPHL01

Development stage: Phase 3
Lead developer: Veradermics
Modality: Small Molecules
Administration: Oral

Overview

VDPHL01 is an investigational, non-hormonal oral drug being developed for the treatment of androgenetic alopecia (AGA), also known as pattern hair loss, in both men and women. It is currently in Phase 2/3 clinical trials. Unlike existing FDA-approved oral treatments for hair loss that act via hormonal mechanisms (such as finasteride), VDPHL01 does not impact hormone levels and aims to avoid associated side effects like sexual dysfunction or cardiovascular issues. The drug is administered as a modified-release tablet—8.5 mg for males and 4.5 mg for females—with dosing once or twice daily over a 12-month period in clinical studies. The precise mechanism of action has not been disclosed, but it is described as having a unique profile compared to current therapies[1][2][4][6][7].

Other names: VDPHL

Beyond the preview

Go deeper on VDPHL01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDPHL01.

Explore the full profile